Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.

Withycombe B, Ovenell M, Meeker A, Ahmed SM, Hartung DM.

J Clin Epidemiol. 2016 Sep;77:78-83. doi: 10.1016/j.jclinepi.2016.04.007. Epub 2016 Apr 22.

PMID:
27108488
2.
3.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866143
4.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866141
5.

Author response.

Hartung DM, Bourdette DN, Ahmed S, Whitham RH.

Neurology. 2015 Nov 10;85(19):1728. No abstract available.

PMID:
26866072
6.

Author response.

Hartung DM, Bourdette DN, Whitham RH.

Neurology. 2015 Nov 10;85(19):1727. No abstract available.

PMID:
26866070
7.

The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program.

Kim H, Hartung DM, Jacob RL, McCarty D, McConnell KJ.

Psychiatr Serv. 2016 Apr 1;67(4):397-404. doi: 10.1176/appi.ps.201500116. Epub 2016 Jan 14.

PMID:
26766755
8.

A chronic opioid therapy dose reduction policy in primary care.

Weimer MB, Hartung DM, Ahmed S, Nicolaidis C.

Subst Abus. 2016;37(1):141-7. doi: 10.1080/08897077.2015.1129526.

PMID:
26685018
9.

Rural-Urban Differences in Chronic Disease and Drug Utilization in Older Oregonians.

Goeres LM, Gille A, Furuno JP, Erten-Lyons D, Hartung DM, Calvert JF, Ahmed SM, Lee DS.

J Rural Health. 2016 Jun;32(3):269-79. doi: 10.1111/jrh.12153. Epub 2015 Oct 30.

10.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

Hartung DM, Bourdette DN, Ahmed SM, Whitham RH.

Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24. Erratum in: Neurology. 2015 Nov 10;85(19):1728.

11.

The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.

Meeker AS, Herink MC, Haxby DG, Hartung DM.

Syst Rev. 2015 Mar 1;4:21. doi: 10.1186/s13643-015-0001-y. Review.

12.

Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication.

Hartung DM, Middleton L, Markwardt S, Williamson K, Ketchum K.

Clin Ther. 2015 Jan 1;37(1):114-123.e1. doi: 10.1016/j.clinthera.2014.10.025. Epub 2014 Nov 25.

PMID:
25465946
13.

Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.

Hartung DM, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR.

J Subst Abuse Treat. 2014 Aug;47(2):113-21. doi: 10.1016/j.jsat.2014.03.007. Epub 2014 Apr 13.

14.

Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.

Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M.

Ann Intern Med. 2014 Apr 1;160(7):477-83. doi: 10.7326/M13-0480.

15.

Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs.

Hartung DM, Zerzan J, Yamashita T, Tong S, Morden NE, Libby AM.

Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):87-94. doi: 10.1002/pds.3538. Epub 2013 Oct 21.

PMID:
24142840
16.

Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population.

Hartung DM, Middleton L, McFarland BH, Haxby DG, McDonagh MS, McConnell KJ.

Psychiatr Serv. 2013 Dec 1;64(12):1236-42. doi: 10.1176/appi.ps.005482012.

PMID:
23999754
17.

Breaking up is hard to do: lessons learned from a pharma-free practice transformation.

Evans D, Hartung DM, Beasley D, Fagnan LJ.

J Am Board Fam Med. 2013 May-Jun;26(3):332-8. doi: 10.3122/jabfm.2013.03.120268.

18.

A pilot study evaluating alternative approaches of academic detailing in rural family practice clinics.

Hartung DM, Hamer A, Middleton L, Haxby D, Fagnan LJ.

BMC Fam Pract. 2012 Dec 31;13:129. doi: 10.1186/1471-2296-13-129.

19.

Role of practice-based research networks in comparative effectiveness research.

Hartung DM, Guise JM, Fagnan LJ, Davis MM, Stange KC.

J Comp Eff Res. 2012 Jan;1(1):45-55. Review.

20.

Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Hartung DM, Middleton L, Svoboda L, McGregor JC.

CNS Drugs. 2012 Aug 1;26(8):707-16. doi: 10.2165/11634260-000000000-00000.

Supplemental Content

Loading ...
Support Center